Sleepiz AG Raises CHF4.4m CHF

Sleepiz AG, a Zürich based medical technology start-up, has raised 4.4m CHF in Series A to expand its portfolio to chronic respiratory disease monitoring. With continuous remote monitoring caregivers can identify and act upon patient deterioration before it is too late.

Sleepiz provides patient-centric disease management through seamless integration of contactless monitoring into people’s homes. The first product of the start-up, Sleepiz One, is a small device that is simply placed next to the patient’s bed. Completely contactless, the Sleepiz One measures human vital signs with medical accuracy. Currently, the first customers in Switzerland and India use the Sleepiz One for sleep apnea screenings, a disorder that affects 1 billion people worldwide but of which only 20% are diagnosed.

In just over three years, the ETH spin-off has grown to a team of more than 50 people including PhDs in engineering, data modelling and signal processing, as well as business and healthcare professionals. Headquartered in Zürich, Switzerland, Sleepiz AG also has its own subsidiary in Pune, India.

The start-up has previously completed a pre-seed round of CHF 300 000 and seed round of CHF 1 million. Investors of the Series A round include Verve Ventures, ZKB, the venture arm of a US health insurance, super angels, and leading healthcare professionals. "Sleepiz pursues a compelling vision of making vital sign monitoring touchless, which is a paradigm shift in the industry and paves the way for a new future of healthcare", Steffen Wagner, Co-CEO Verve Ventures, lead investor of the Series A.

Fightig COPD and COVID-19

The newly raised capital will support Sleepiz expansion of its current offering. Chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), as well as recently COVID-19, are one of the leading causes of death worldwide. With continuous remote monitoring and timely interventions, these deaths can be prevented. The next generation of Sleepiz One, Sleepiz One Connect, integrates additional measurements and an enhanced telehealth platform for more actionable insights. By remotely monitoring patient’s respiration rate and patterns together with SpO2 measurements, the Sleepiz telehealth platform helps caregivers identify and act upon patient deterioration before it is too late. The Sleepiz telehealth CARE team, equipped with professionally trained specialists, adds another safety layer by keeping an eye on the patients 24/7.

Sleepiz has already successfully completed its clinical investigations with leading clinics and key opinion leaders in the DACH market. With these early successes, Sleepiz aims to expand its core markets and enter the rest of Europe and the US. Additionally, the raised capital will enable Sleepiz to classify as a Class IIa medical device under the European medical device regulation.

(Press release / SK)